The list of IT vendors and service providers that have yet to strike a deal with AstraZeneca in 2015 keeps getting shorter. Assay Depot is the latest name to cross of the list after the scientific services marketplace agreed to create a private research e-commerce platform for AstraZeneca.
Google has given the world a peek at one of the ways in which it thinks algorithms and huge datasets could reshape drug discovery. The work involves trying to make virtual drug screening more efficient using the same ethos Google applies to most problems: More data, more computing power. Read more >>
President Obama has made the creation of a huge, technically challenging database the centerpiece of his precision medicine proposal. The initiative will draw on existing resources and new studies to gather data on the biology, behavior and health of more than 1 million people. Read more >>
POPULAR COMMENT THREADS
Having faced years of criticism for its failure to publish guidelines on how the industry can use social media, the FDA is now being chastised by the advocacy group Union of Concerned Scientists over its lack of a policy for its staff.
Cincinnati Children's Hospital Medical Center has received $2.2 million from the National Institutes of Health (NIH) to track children who have rare genetic disorders.
Analysts at MarketsandMarkets have looked into their crystal ball and come up with a forecast of the pharmacovigilance and drug safety software sector. The authors predict the value of the market will top $150 million by 2019, with Asia and Latin America tipped to be the driving forces behind growth over the next few years.
Harvard geneticist George Church has backed Open Humans, an online platform that asks people to openly share their genomes and other personal data. The idea is to marry the underlying principles of the open-source and quantified-self movements to make more data available to more researchers.
An independent committee set up to probe a dispute over Europe's $1 billion Human Brain Project (HBP) has sided with critics of the initiative. The outcome leaves the fate of HBP and its ambitious and much-criticized plan to simulate the brain using a supercomputer in doubt.
The United Kingdom has wasted no time getting industry involved with its 100,000 Genomes Project. With just 3% of the sequencing work done, Genomics England has enlisted the help of a who's who of Big Pharma companies to pore over the data in search of new avenues for drug discovery.
From Our Sister Sites
X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.
Through a storm of M&A activity, Actavis CEO Brent Saunders has climbed his way up into the CEO's chair at one of pharma's top 10 drugmakers--and it's a climb for which he's been well rewarded.